Concomitant Curcumin Palliative Radiotherapy in Advanced Cervical Cancer Trial

Cervical Cancer Clinical Trial

— CuPRAC  

Official title:

Feasibility, Safety, and Efficacy of Concomitant Curcumin in Patients Undergoing Palliative Radiotherapy for FIGO Stage IIIB-IVA Cervical Cancer: An Open-label Pilot Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05947513
• Other study ID #: 001/21/SoP
• Status: Not yet recruiting
• Phase: Phase 1/Phase 2
• Start date: October 2023
• Est. completion date: November 2024

Study information

• Verified date: July 2023
• Source: Addis Ababa University
• Contact: Biniyam Girma, Bpharm, MSc
• Phone: 093-708-9518
• Email: biniyam.girma[@]ju.edu.et
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to test curcumin as an adjunct treatment in patients with cervical cancer receiving standard-of-care palliative radiation. The main questions it aims to answer are:

• Is adding curcumin to standard-of-care palliative radiotherapy of cervical cancer patients safe?

• Does adding curcumin to standard-of-care palliative radiotherapy of cervical cancer patients improve therapeutic responses?

• How much curcumin is absorbed into the body and how long will it stay in the body?

Participants will:

• Take two 500 mg curcumin capsules twice per day for 4-6 weeks in addition to the prescribed palliative radiotherapy.

• Provide blood and urine samples for laboratory tests.

• Provide blood samples to measure curcumin levels in their body.

• Obtain CT-scan to measure their tumor response.

• Complete questioners to measure improvements to their quality of life, if any.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 19
• Est. completion date: November 2024
• Est. primary completion date: November 2024
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

• Age >18 years old (Adult, Older Adult)

• Histologically confirmed squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma of the cervix, FIGO stage IIIB-IVA

• Undergoing for standard of care palliative radiotherapy without chemotherapy as per the local treatment guideline

• Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, 2

• Adequate liver function (aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =2.5 x ULN (Upper Limit of Normal); total serum bilirubin =1.5 x ULN); blood cell counts (absolute neutrophils count =1.500/mm3; platelet count =100.000/mm3; hemoglobin =10.0 g/dL); renal function (serum creatinine =1.5 x ULN; estimate creatinine clearance (Cockcroft-Gault) =60 mL/min)

• Participants must have measureable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST) V1.1.

• Agree to use an effective form of contraception (e.g., true abstinence (not periodic abstinence), barrier contraception, highly effective hormonal contraception) if the participant is of child bearing age

• Give informed consent

Exclusion criteria:

• Cervical cancer patients who are candidates for single dose palliative radiotherapy

• Patients with hydronephrosis

• Evidence of distant metastases

• Receiving any other investigational agent concurrently or within the last 4 weeks before enrollment

• Received any previous radiation or chemotherapy for cervical cancer

• Underwent surgery in the four weeks prior to the enrolment date or scheduled to undergo surgery within eight weeks after end of treatment

• Currently using of any chemotherapy or scheduled to receive within eight weeks after end of treatment

• Known allergy to turmeric or its derivatives (ginger, curry, cumin, or cardamom)

• Known allergy to fenugreek, peanut, soy, lentil, pea, bean, and chickpea

• Presence of conditions that precludes the safe administration of the trial intervention and/or prohibit adequate compliance to study requirements including chronic ongoing infections (like HIV, Hepatitis B or C), uncontrolled hypertension, heart failure, cardiac arrhythmia, unstable angina, chronic obstructive lung disease, diabetes mellitus, chronic renal disease, chronic liver disease, biliary tract obstruction or cholelithiasis, gastric or duodenal ulcers, autoimmune or inflammatory disorders, a coagulation or platelet disorder, seizure disorders and psychiatric illness. Patients with disorders other than the ones specified above may also be excluded based on the judgment of the principal investigator.

• Pregnant and breastfeeding women

• Participants with circumstances that will not permit completion of the study or required follow-up. For instance, if travel to and from treatment site is an issue.

Related Conditions & MeSH terms

• Cervical Cancer
• Uterine Cervical Neoplasms

Intervention

Drug:
• Curcumin
Curcumin formulation with enhanced bioavailability which contains food-grade curcumin 35% (w/w) combined with the galactomannan fiber from fenugreek seeds.

Radiation:
• Palliative radiotherapy
As per the treatment guidelines of the Tikur Anbessa Hospital Radiotherapy Center, standard-of-care palliative or non-radical radiotherapy entails treatment of advanced cervical cancer patients at a biologically effective dose of 45-55 Gy over the course of three to five weeks.

Locations

Country	Name	City	State
n/a

Sponsors (3)

Lead Sponsor	Collaborator
Addis Ababa University	Akay Natural Ingredients Private Limited, Center for Innovative Drug Development and Therapeutic Trials for Africa, Addis Ababa University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of participants without treatment-related toxicities leading to premature termination of treatment		From initiation (Day 1) up to end of treatment over 4-6 weeks
Primary	Objective Response Rate (ORR)	Objective Response Rate is defined as proportion of participants having a complete response (CR) or partial response (PR) as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.	Time Frame: 13-17 weeks
Primary	Incidence of Treatment-Emergent Adverse Events (TEAEs) as Assessed by CTCAE v5.0	Any new or worsening of a pre-existing untoward sign, symptom, or disease, including a clinically significant laboratory or vital sign abnormality during study treatment, is defined as a treatment emergent adverse event.	Up to 10-14 weeks from treatment initiation
Primary	Incidence of Dose Interruption in curcumin and radiotherapy regimens	A Dose Interruption is defined a zero dose given on one or more days on which the protocol-specified dose is non-zero, followed by resumption of dosing.	From initiation (Day 1) up to end treatment over 4-6 weeks
Primary	Incidence of Dose Reduction in curcumin and radiotherapy regimens	A dose reduction is a decrease in dose from the protocol planned starting dose or a decrease from the previous non-zero dose, even if this decrease has been directly preceded by an interruption.	From initiation (Day 1) up to end treatment over 4-6 weeks
Primary	Dose Intensity (DI) of curcumin and radiotherapy	Dose intensity is defined as cumulative dose divided by the treatment duration in weeks.	From initiation (Day 1) up to end treatment over 4-6 weeks
Primary	Relative Dose Intensity (RDI) of curcumin and radiotherapy	Relative dose intensity is defined as dose intensity (actual DI) divided by the protocol weekly dose (planned DI), expressed as a percentage.	From initiation (Day 1) up to end treatment over 4-6 weeks
Secondary	Disease Control Rate (DCR)	Disease control rate (DCR): proportion of participants having a complete response (CR) or partial response (PR) or stable disease (SD) as defined by the RECIST 1.1 criteria.	13-17 weeks
Secondary	Change from baseline in Health-Related Quality of Life (QOL) as assessed using EORTC QLQ-C30 at 7-9 weeks	The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) measures quality of life in cancer patients by evaluating physical, psychological, and social functions. Possible scores range from zero to 100, with a higher scale score indicating a higher response level. As such, high scores on functional and global health status (QoL) scales indicate healthy levels of functioning and high quality of life, respectively. However, a high score on the symptoms scale or item indicates more problems or symptomatology.	Baseline, 7-9 weeks
Secondary	Change from baseline in Health-Related Quality of Life (QOL) as assessed using EORTC QLQ-C30 at 13-17 weeks	The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) measures quality of life in cancer patients by evaluating physical, psychological, and social functions. Possible scores range from zero to 100, with a higher scale score indicating a higher response level. As such, high scores on functional and global health status (QoL) scales indicate healthy levels of functioning and high quality of life, respectively. However, a high score on the symptoms scale or item indicates more problems or symptomatology.	Baseline, 13-17 weeks
Secondary	Change from baseline in Health-Related Quality of Life (QOL) as assessed using EORTC QLQ-CX24 at 7-9 weeks	The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Cervical Cancer Module (EORTC QLQ-CX24) measures quality of life in cervical cancer patients in combination with the QLQ-C30. Possible scores range from zero to 100 for all scale and single-item measures. While a high score on the functional single-items indicates a high degree of functioning, a high score on the symptom scales or single-items indicates a high level of symptomatology or difficulties.	Baseline, 7-9 weeks
Secondary	Change from baseline in Health-Related Quality of Life (QOL) as assessed using EORTC QLQ-CX24 at 13-17 weeks	The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Cervical Cancer Module (EORTC QLQ-CX24) measures quality of life in cervical cancer patients in combination with the QLQ-C30. Possible scores range from zero to 100 for all scale and single-item measures. While a high score on the functional single-items indicates a high degree of functioning, a high score on the symptom scales or single-items indicates a high level of symptomatology or difficulties.	Baseline, 13-17 weeks
Secondary	Peak Plasma Concentration (Cmax) of CGM Curcumin	Peak Plasma Concentration represents the highest observed curcumin concentration observed in plasma over all PK sample concentrations following single-dose CGM Curcumin administration.	Pre-dose and 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12 hours post-dose
Secondary	Time to Peak Plasma Concentration (Tmax) of CGM Curcumin	Time to Peak Plasma Concentration (Tmax) represents the time when Cmax of curcumin occurs following single-dose CGM Curcumin administration.	Pre-dose and 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12 hours post-dose
Secondary	Area under the Plasma Concentration versus Time Curve (AUCt) of CGM Curcumin	Area under the Plasma Concentration versus Time Curve (AUCt) represents the area under the concentration-time curve of curcumin from time zero to the time of the end of dosing interval following single-dose CGM Curcumin administration.	Pre-dose and 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12 hours post-dose
Secondary	Half-life (T1/2) of CGM Curcumin	Half-life (T1/2) represents the time for plasma concentration of curcumin to fall by a factor of one-half in the terminal phase following single-dose CGM Curcumin administration.	Pre-dose and 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12 hours post-dose
Secondary	Recruitment Rate	Recruitment Rate is defined as the proportion of those who participate in the trial who were approached as potential participants.	through study completion, an average of 1 year
Secondary	Assessment Completion Rate	Assessment Completion Rate is defined as the proportion of assessments that could be completed as planned.	through study completion, an average of 1 year
Secondary	Attrition Rate	Attrition Rate is defined as the proportion of participants who withdraw from the study.	through study completion, an average of 1 year